Obesity in HIV After Antiretroviral Therapy

NCT ID: NCT01461876

Last Updated: 2015-10-14

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2009-11-30
• Study Completion Date: 2014-05-31

Brief Summary

This is a retrospective longitudinal study that evaluates the prevalence and incidence of overweight/obesity within an HIV-infected population before and after 12 and 24 months of a stable antiretroviral therapy (ART). The study group will be compared to the weight of a healthy, matched population that is not infected with HIV. The primary hypothesis states that the proportion of HIV-infected persons newly classified as overweight/obese will increase by ≥20% after 12 months of initial ART, and this incidence will be greater than that of a matched HIV-uninfected control population. The effect of immune function variables, such as CD4, HIV viral load, and ART regimen on weight will be analyzed. In addition, the study will analyze the effect of weight and immune function markers on the inflammatory markers, high sensitivity C-reactive protein (hsCRP) and D-dimer. An HIV samples repository will be used for specimens to be assayed for hsCRP and D-dimer.

Conditions

HIV; AIDS; Obesity

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: RETROSPECTIVE

Study Groups

HIV-infected cohort

antiretroviral therapy

Intervention Type: DRUG

Standard of care antiretroviral therapy

HIV-uninfected control group

No interventions assigned to this group

Interventions

antiretroviral therapy

Standard of care antiretroviral therapy

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Treatment-naive at study entry;

2. Subjects will need to remain on ART for 12 months as initiated with substitution allowed for toxicity management within the same class of drug;

3. Subjects within this group that remain on ART for an additional 12 months (total 24 months) as initiated with substitution allowed for toxicity management within the same class of drug will continue to be followed longitudinally for the 24 month period;

4. Availability of repository samples.

Followed in the Duke Primary Care Clinics during the years of inclusion with available data on weight, race and gender.

Exclusion Criteria

1. Pregnancy during period of observation or within 6 months of study entry;

2. Malignancy (other than squamous or basal cell carcinomas of the skin);

3. Newly diagnosed thyroid disorder within 6 months of study entry;

4. Use of megace or marinol;

5. Long-term use of glucocorticoids (greater than 1 month of prednisone 5mg or higher or an equivalent dose of another glucocorticoid);

6. Use of androgenic steroids;

7. History of diabetes or use of glucose-lowering agents;

8. Use of the following psychiatric or anticonvulsant agents- thioridazine, olanzapine (zyprexa), clozapine (clozaril), quetiapine (seroquel), risperidone (risperdal), lithium, remeron, paxil, valproate, carbamazepine, gabapentin;

9. Concurrent treatment for hepatitis C infection;

10. Diagnosis of a new opportunistic infection (OI) as defined by the CDC during the 1st 12 months of ART.22 OIs include the following: PCP, toxoplasmosis, MAC, histoplasmosis, candidiasis, cryptococcus, coccidiodes, CMV, cryptosporidium, microsporidiosis, tuberculosis, bartonellosis, herpes simplex virus, HHV-8, human papillomavirus;

11. Diagnosis of congestive heart failure and receiving diuretic therapy;

12. End stage renal disease.

1. Pregnancy during period of observation or within 6 months of study entry;

2. Malignancy (other than squamous or basal cell carcinomas of the skin);

3. Newly diagnosed thyroid disorder within 6 months of study entry;

4. Long-term use of glucocorticoids (greater than 1 month of prednisone 5mg or higher or an equivalent dose of another glucocorticoid);

5. Use of androgenic steroids;

6. History of diabetes or use of glucose-lowering agents;

7. Use of the following psychiatric or anticonvulsant agents- thioridazine, olanzapine (zyprexa), clozapine (clozaril), quetiapine (seroquel), risperidone (risperdal), lithium, remeron, paxil, valproate, carbamazepine, gabapentin;

8. Treatment for hepatitis C infection during observation period;

9. Diagnosis of congestive heart failure and receiving diuretic therapy;

10. End stage renal disease.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Janssen, LP

INDUSTRY

Sponsor Role: collaborator

Duke University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Wanda Lakey, MD, MHS

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

Duke University Medical Center

Durham, North Carolina, United States

Countries

United States

Other Identifiers

Pro00020911

Identifier Type: -

Identifier Source: org_study_id